挥发性组学用于代谢功能障碍相关脂肪性肝病的诊断与风险分层:一项概念验证研究
这项前瞻性单中心研究用电子鼻分析呼气挥发性有机化合物,纳入Child-Turcotte-Pugh A级MASLD肝硬化30例、非肝硬化MASLD 30例和健康志愿者30例。呼气谱区分MASLD与健康志愿者的敏感性为100%(p<0.001,交叉验证96%),并将MASLD分为三个预后不同的亚组。
要点
- 电子鼻呼气谱区分MASLD与健康志愿者敏感性100%(p<0.001),交叉验证96%。
- 无偏聚类将MASLD分为三个基线特征相似但预后不同的亚组。
- Cluster 2在5年随访中疾病进展42%(p=0.03)、肝相关失代偿事件17%(p=0.06)、全因死亡12.5%。
核心结论
- 电子鼻可区分MASLD患者与健康志愿者,并通过无偏聚类识别预后显著更差的患者。
- 这些结果需要在独立的MASLD人群中进行前瞻性验证。
研究设计与样本
- 前瞻性单中心研究,使用电子鼻分析呼气挥发性有机化合物。
- 队列包含Child-Turcotte-Pugh A级MASLD肝硬化患者30例、非肝硬化MASLD患者30例和健康志愿者30例。
- 采用无偏机器学习聚类技术,并对患者队列收集5年纵向临床数据。
- 进行逻辑回归和单变量分析以识别疾病进展、肝相关结局和全因死亡的危险因素。
主要发现
- 呼气挥发性有机化合物的主成分分析区分MASLD患者与健康志愿者,敏感性100%(p<0.001,交叉验证验证96%),不受年龄和性别影响。
- 电子鼻呼气谱将MASLD患者分为三个基线临床和人口学特征相似但预后显著不同的亚组。
- 在5年随访期间,Cluster 2被确定为进展风险较高亚组(42%,p=0.03)。
- Cluster 2的肝相关失代偿事件为17%(p=0.06),全因死亡为12.5%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Human breath contains numerous volatile organic compounds (VOCs) produced by physiological and metabolic processes or perturbed in pathological states. Electronic nose (eNose) technology has been extensively validated as a non-invasive diagnostic tool for respiratory disease. Using eNose-derived exhaled breath signals, we investigated whether it could discriminate patients with metabolic dysfunction-associated steatotic liver disease (MASLD) from healthy volunteers and identify patients at high risk of disease progression. METHODS: In a prospective single-centre study, exhaled breath VOCs were analysed using an eNose, in a well-characterised cohort comprising patients with Child-Turcotte-Pugh class A MASLD cirrhosis (n = 30), non-cirrhotic MASLD (n = 30) and healthy volunteers (n = 30). An unbiased machine learning clustering technique was applied. Longitudinal clinical data were collected over 5 years for the patient cohort. Logistic regression and univariable analysis were performed to identify risk factors for disease progression, liver-related outcomes, and all-cause mortality. RESULTS: Principal component analysis of breath VOCs discriminated patients with MASLD from healthy volunteers with 100% sensitivity (p < 0.001, cross-validation verification of 96%), independent of age and gender. The eNose breath profile classified patients with MASLD into three distinct subgroups with similar baseline clinical and demographic characteristics but markedly different prognoses. During the 5-year follow-up period, Cluster 2 was identified as a higher-risk subgroup for progression (42%, p = 0.03), liver-related decompensation events (17%, p = 0.06), and all-cause mortality (12.5%). CONCLUSION: eNose can discriminate patients with MASLD from healthy volunteers and, using unbiased clustering analysis, identify patients with a significantly worse prognosis. These results warrant prospective validation in independent MASLD populations. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02950610.
引用
- Sinha R, Gillespie SL, Brinkman P, et al. Volatomics for Diagnosis and Risk Stratification of MASLD: A Proof-Of-Concept Study. Aliment Pharmacol Ther. 2025. PMID: 40391721. doi:10.1111/apt.70176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。